VBI Vaccines

$2.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.23 (+9.24%) Today
-$0.02 (-0.74%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell VBI Vaccines and other stocks, options, and ETFs commission-free!

About VBIV

VBI Vaccines, Inc. New Common Stock (Canada), also called VBI Vaccines, is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA. The listed name for VBIV is VBI Vaccines, Inc. New Common Stock (Canada).

CEO
Jeffrey R. Baxter
Employees
125
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
658.38M
Price-Earnings Ratio
Dividend Yield
Average Volume
6.63M
High Today
$2.77
Low Today
$2.44
Open Price
$2.49
Volume
6.26M
52 Week High
$6.93
52 Week Low
$0.685

Collections

VBIV Earnings

-$0.22
-$0.15
-$0.07
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 4, Pre-Market

You May Also Like